Ascendiant Capital Maintains Buy on Allarity Therapeutics, Raises Price Target to $11.25

Benzinga · 3d ago
Ascendiant Capital analyst Edward Woo maintains Allarity Therapeutics (NASDAQ:ALLR) with a Buy and raises the price target from $11 to $11.25.